Genexine: Rights offering (paid-in capital increase) decision
This is a major-event filing in which Genexine reports its board has decided to raise money by issuing new shares for cash, which can increase the number of shares outstanding. Details such as size, price, and purpose appear in the filing itself, and I haven't been given them here. Genexine filed this on Oct 16, 2026.
High impactPredicted impact: High· Actual: −9.9% vs sector, volume 0.4× normal (5 trading days)
Rights offering decision; new shares may be large, and the company's revenue is tiny versus its market value.
Company filing